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(Figure 1) each of which could contribute, 
individually and / or in synergy, to the 
reduction in renal  brosis. ' e tricyclic 
compounds have analgesic e8 ects, inde-
pendent of their antidepressant proper-
ties, on chronic pain associated with 
rheumatologic conditions, postherpetic 
neuralgia, or diabetic neuropathy even in 
low amounts such that the 1  mg / kg / d oral 
dose used by Achar  et al. 2 to block renal 
 brosis is not an excessive dose. One area, 
not developed by the authors, where 
amitriptyline treatment could have an 
impact on kidney fibrosis is related to 
ceramide metabolism and its role as a 
stress-response molecule in cell apoptosis 
and inJ ammation. First, however, the util-
ity of the UUO model in the study of renal 
fibrosis needs to be established. This 
model is gaining in popularity such that 
at the 2008 annual meeting of the Ameri-
can Society of Nephrology, almost 60 
abstracts, nine of which were selected for 
oral presentation, used this model to study 
mechanisms of and the possible treatment 
of kidney  brosis. 
 InJ ammation of the kidney tubulointer-
stitium results in  brosis, which is a major 
factor in the progressive loss of renal func-
tion in patients with a wide variety of kid-
ney diseases. Over two-thirds of the 
kidney volume is composed of tubular 
epithelial cells, with the remainder resid-
ing in the glomerular and the interstitial 
spaces. Most of the interstitial cells are 
associated with the rich vascular network 
of the kidney along with a small number 
of tenant mononuclear cells and  bro-
blasts. UUO is a model of renal  brosis, 
encompassing many aspects of other 
forms of kidney disease, such as those 
caused by streptozotocin, cyclosporin, 
aminonucleoside, adriamycin, angiotensin 
II, and ischemia – reperfusion. ' is is a 
highly reproducible model applicable to 
fetal, neonatal, and adult animals that fea-
tures in ltration of the kidney by mono-
cytes and macrophages, fibroblast 
differentiation and proliferation, and 
increased extracellular matrix protein 
deposition. In an attempt to maintain the 
integrity of tubules, there is activation of 
proliferative pathways within the epithe-
lial cells to repopulate themselves. If the 
proliferative forces or homeostatic factors 
within the kidney dissipate, apoptosis 
overwhelms the ability of tubular epithe-
lial cells to survive, and tubular atrophy 
ensues, thus furthering the loss of kidney 
function. ' is UUO model has been used 
to test the contribution of epithelial – mes-
enchymal transdifferentiation to the 
formation of myo broblasts positive for 
  -smooth muscle actin or  broblast-spe-
ci c protein-1 (FSP-1, or S100A4) within 
the interstitium. Features associated with 
the progression of renal  brosis occur in 
an accelerated time frame, allowing inves-
tigators to use this model to gain valuable 
information on pathophysiologic mecha-
nisms of the initiation and progression of 
renal  brosis. ' ese mechanisms and the 
contributions of angiotensin II, trans-
forming growth factor-  , and tumor 
necrosis factor-  to kidney  brosis have 
been extensively reviewed by Klahr and 
Morrissey 3 and more recently by Misseri 
and Meldrum, 4 Bascands and Schanstra, 5 
and Chevalier. 6 Because this is a unilateral 
disease model, there is no overt hyperten-
sion or uremia to complicate the interpre-
tation of results. Operational assessment 
of the formerly obstructed kidney can be 
made following relief of the obstruction 
by measurement of individual kidney 
function 3,7 or by reimplantation of the 
obstructed ureter and nephrectomy of the 
contralateral kidney to serially measure 
kidney function in the same test animals. 8 
Overall, UUO is a useful model of kidney 
injury and can be used to test therapeutic 
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 On the basis of their previous work, using 
amitriptyline to relax smooth muscle, 1 
Achar  et al. 2 (this issue) treated mice with 
unilateral ureteral obstruction (UUO) 
with this multifaceted antidepressant and 
found that it inhibited the progression of 
renal  brosis. In particular, there was a 
signi cant reduction in the in ltration of 
the interstitium by CD68-positive macro-
phages, a result equivalent to that of pre-
treatment of the mice with mycophenolate 
mofetil or whole-body X-irradiation prior 
to the obstruction. In addition, there were 
signi cant reductions in the expression of 
  -smooth muscle actin, osteopontin, 
transforming growth factor-  , monocyte 
chemotactic protein-1, and intercellular 
adhesion molecule-1 due to antidepres-
sant treatment. ' e decreased expression 
of these indices of kidney fibrosis was 
equivalent or superior to their reductions 
by either immune-suppressor pretreat-
ment. ' e question here is: how does an 
antidepressant accomplish this o8 -label 
reduction in kidney  brosis? ' e authors 
pose several mechanistic possibilities 
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 Unilateral ureteral obstruction is a well-established model of renal 
fibrosis used by many investigators to test various compounds for their 
ability to ameliorate kidney disease. Achar  et al. treated ureterally 
obstructed mice with the tricyclic antidepressant amitriptyline and 
found that this inhibited inflammation, myofibroblast formation, and 
several other indices of renal fibrosis. This pleiotropic antidepressant 
agent appears to have antifibrotic effects in the kidney and other organ 
systems. 
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strategies for reversing renal fibrosis 
and preserving or restoring renal 
function. 
 Amitriptyline and other tricyclic anti-
depressants fit into this discussion by 
virtue of their ability to cause degradation 
of acid sphingomyelinase, 9 an enzyme 
contributing to ceramide formation that 
is best known for its involvement in the 
lysosomal-storage disorder Niemann –
 Pick disease. Modulation of ceramide lev-
els by tricyclic antidepressants has been 
used to decrease lung injury in experi-
mental cystic  brosis 10 and liver cirrho-
sis, 11 but at higher doses than Achar  et al. 2 
used. Mice de cient in acid sphingomy-
elinase were found to be resistant 
to cisplatin-induced gastrointestinal 
damage, 12 and hepatocytes from such 
mice had decreased copper-induced 
apoptosis. 11 Thus, extrapolating from 
these studies, a beneficial effect of 
amitriptyline in the UUO study of Achar 
 et al. 2 could be an inhibition of acid 
sphingomyelinase that, in turn, inhibits 
tubular-cell apoptosis and interstitial 
inJ ammation. ' is coupled with e8 ects of 
amitriptyline on cytokine release, cited by 
the authors, could account for the reno-
protective e8 ects of the antidepressant in 
the UUO model. A signi cant diminution 
in the measured indices of renal  brosis 
apparently occurred between 3 and 5 days 
of ureteric obstruction when the 
amitriptyline was given at the time of the 
obstruction. It would be interesting to give 
the antidepressant at di8 erent times aG er 
initiating renal  brosis to see whether this 
is a true viable treatment option and not 
just a preventive measure. Studies using 
mice in which the acid sphingomyelinase 
gene has been knocked out would help to 
show whether the protective effect of 
amitriptyline is indeed dependent on this 
enzyme or whether there are additional 
pleiotropic e8 ects involving other meta-
bolic pathways. ' e issue of redundant 
functional genes masking changes in gene 
activity in gene knockout mice in the UUO 
model has been addressed previously. 3,5 
 On the basis of this study and their 
long-standing use for mood alteration, 
Achar  et al. 2 suggest that the tricyclic anti-
depressants may be used as future thera-
pies to inhibit the progression of renal 
disease. ' is class of drugs, however, is 
not without unintended consequences, so 
patient monitoring is essential. ' ese side 
e8 ects ( Toxnet.nlm.nih.gov ) include, but 
are not limited to, dry mouth, orthostatic 
hypotension, and tachycardia. It may turn 
out, however, that an unintended conse-
quence of the tricyclic antidepressants is 
a viable treatment delaying or reversing 
the progression of renal  brosis, thus main-
taining or restoring kidney function. 
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 Figure 1  |  Pleiotropic effects of tricyclic antidepressants. 
